



Norgine receives first approval for Moviprep®

6 March 2006

Norgine, the European specialty pharmaceutical company, today announced that it has received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for MOVIPREP (NRL994). The product is indicated for bowel cleansing prior to any clinical procedures requiring a clean bowel e.g. bowel endoscopy, radiology or digestive tract surgery.

Commenting on the UK licence Peter Martin, Chief Operating Officer said “This is an exciting start to our centenary year. MOVIPREP is an important addition to our gastroenterology portfolio”.

In December 2005, Norgine granted Salix Pharmaceuticals the exclusive rights to market MOVIPREP in the USA. MOVIPREP is currently being reviewed by the U.S. Food and Drug Administration.

ENDS

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for 100 years and has a presence in all the major European markets. In 2005 Norgine’s sales were €171 million, the 19th consecutive year of double-digit growth. The company employs over 900 people, of which 350 are in sales and marketing.

Norgine’s current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. Movicol® for the treatment of chronic constipation and faecal impaction, Klean-Prep® for bowel preparation prior to colonoscopy,

and Oramorph® for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has products at various stages of clinical development. Norgine has two manufacturing sites; Hengoes in the UK and Dreux, France.

Norgine's website is www.norgine.com

For further information, please contact:

Paul Pay, Vice-President, Business Development, Norgine

T: +44 (0)1895 453710

E: ppay@norgine.com

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: lblakeborough@chapterfive.co.uk